N. prodotti: 0
Totale ordine: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
THERAPY RESPONSE IN NUCLEAR MEDICINE
Guest Editor: Bombardieri E.
Del Vecchio S. 1, Zannetti A. 1, Aloj L. 1, Salvatore M. 2
1 Center for Nuclear Medicine, Consiglio Nazionale delle Ricerche “Federico II” University, Naples, Italy
2 Department of Biomorphological and Functional Sciences “Federico II” University, Naples, Italy
Evaluation of treatment response is of primary importance in the management of patients with cancer. Both positron- and γ-emitting compounds have been used to monitor changes in tumor metabolism or viability after therapy. The use of 99mTc-labeled lipophilic cations raised the possibility to predict the tumor response to treatment and to identify patients who will become refractory to subsequent therapy. In particular, many studies have shown the prognostic value of 99mTc-MIBI scan in different types of malignancy including breast and lung cancer, lymphoma and sarcoma. The ability of 99mTc-MIBI to interact with P-glycoprotein, allowing the functional assessment of the multidrug resistant phenotype, is one of the mechanisms underlying its prognostic value. Additional mechanisms of cell resistance, mainly involving alterations of apoptosis, may affect 99mTc-MIBI uptake in tumors. Therefore, either an enhanced tracer clearance or a reduced early uptake of 99mTc-MIBI indicate a poor response to therapy. In both cases, 99mTc-MIBI scan may ensure that the further management strategy will be effective in individual cancer patients.